Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients

Area of Science:

• Nephrology and Immunology
• Transplantation Science
• Immunosuppression Research

Background:

• Optimal induction immunosuppression for kidney transplant recipients without pre-existing donor-specific antibodies (DSAs) remains unclear.
• The virtual crossmatch (VXM) is a critical step in identifying compatible donor-recipient pairs.
• Understanding induction therapy's impact on de novo DSA (dnDSA) development is vital for long-term graft survival.

Purpose of the Study:

• To compare the incidence of de novo donor-specific antibodies (dnDSA) following kidney transplantation.
• To evaluate graft outcomes in patients with a negative virtual crossmatch (VXM) based on induction therapy.
• To identify potential associations between specific induction agents and dnDSA development.

Main Methods:

• Retrospective analysis of 782 kidney transplant recipients with a negative VXM.
• Induction therapies included alemtuzumab, basiliximab, and anti-thymocyte globulin (ATG).
• Kaplan-Meier analysis and multivariate regression assessed dnDSA incidence and graft survival.

Main Results:

• One-year graft survival was high across all groups (>98%) and acute rejection was low (<2%).
• Alemtuzumab induction was associated with a significantly higher incidence of dnDSA (14%) compared to basiliximab (5%) and ATG (8%) at 1 year.
• Multivariate analysis confirmed alemtuzumab's independent association with increased dnDSA risk (HR 2.5).

Conclusions:

• In kidney transplant recipients with a negative VXM, alemtuzumab is associated with a higher rate of dnDSA development.
• Despite increased dnDSA, alemtuzumab use did not negatively affect 1-year graft survival or acute rejection rates.
• Further research is needed to elucidate the clinical significance of dnDSA in the context of alemtuzumab induction.